CD5 and diffuse large B-cell lymphoma: Niitsu et al. in a cohort of 930 DLBCL patients found that the 5-year OS rate was 55% and 65% for CD5+ DLBCL (n = 102) and CD5- DLBCL (n = 828), respectively, while the 5-year PFS rates were 52% and 61%, respectively.